House
Sign inCreate account
Drug lookup
Drug reference

methylergonovine

Ergot alkaloid · Uterotonic

Ergot alkaloidUterotonic
CDSCO approved
EXCRETION
—
not curated
INTERACTIONS
—
none in our sources
PREGNANCY
—
not curated

Mechanism

Not yet extracted

Indications

Prevention of postpartum hemorrhage

Side effects

Common
Prolonged duration and increased force of uterine contraction (dose-dependent)Sustained uterine contracture (at high doses)
Serious
  • Hallucinations (at supratherapeutic levels)

Related guidelines

Postpartum haemorrhage
FOGSI · Obstetrics & Gynaecology · 2024
Stroke and TIA — secondary prevention
AHA · Neurology · 2021
Tobacco-related cancer prevention
ICMR · Oncology · 2021
Cardiovascular disease prevention
ESC · Cardiology · 2021
Primary prevention of cardiovascular disease
AHA · Cardiology · 2019

Other Ergot alkaloid drugs

ergonovine
0 brands
ergotamine
0 brands
ergotoxine
0 brands
methysergide
0 brands

Ask House about methylergonovine

Continue into a citation-backed clinical answer with the drug context already attached.

Open in workspaceAsk House about this drug

Sources: Goodman & Gilman 14e·Verified: 2026-05-10 · House clinical team